LIBYAN JOURNAL OF MEDICINE 2018 VOL 13 1466573 httpsdoiorg1010801993282020181466573 Incorporation p53 mutation status Ki67 proliferating index classifying Her2neu positive gastric adenocarcinoma Ayesha Ahmed Dalal M AlTamimi Department Pathology College Medicine King Fahd Hospital Imam Abdulrahman Bin Faisal University Dammam Saudi Arabia ARTICLE HISTORY Received 13 January 2018 Accepted 9 April 2018 KEYWORDS p53 Ki67 Her2neu gastric adenocarcinoma ABSTRACT Her2neu overexpression pathogenetic therapeutic controversial prognostic role gastric cancer p53 mutation status Ki67 proliferation index established prognostic markers tumors In study evaluated p53 Ki67 relation Her2neu positive negative gastric adenocarcinoma GA This crosssectional study carried King Fahd Hospital Imam Abdulrahman bin Faisal University Fifty cases GA retrieved pathology archives Clinicopathological parameters evaluated Immunohistochemical protein analysis Her2neu Ki67 p53 carried Fluorescent situ hybridization FISH analysis Her2neu positive cases showing 2 immunoexpression Frequency Ki67 p53 positivity Her2neu positive cases calculated compared Her2neu negative cases Correlation clinicopatological parameters Her2 positive negative cases p53 mutation status Ki67 proliferation index carried Her2neu overexpression present 12 n 6 cases A high Ki67 seen predominantly Her2neu positive cases 83 n 5 Her2neu negative cases n 44 showed moderate 3188 n 14 low 34 n 15 Ki67 Diffuse p53 positivity seen predominantly Her2neu positive cases 3333 n 2 Focal p53 seen mainly Her2neu negative cases 568 n 25 Negative p53 seen independent Her2neu status Her2neu positivity strongly associated diffuse p53 muta tion status high Ki67 proliferation Her 2neu negative status associated focal p53 positivity low moderate Ki67 proliferation index Such stratifications prognostic markers predictive patients prognostics form basis molecular classification gastric cancer 1 Introduction Gastric cancer common aggres sive malignant tumors worldwide high mortality rate preceded lung cancer 1 Globally gastric cancer fourth common cancer second leading cause cancer related mortality 5year overall survival rate 25 2 role gastric Her2neu overexpression pathogenetic ther apeutic prognostic cancer Evaluation Her2neu overexpression targeted therapies currently mainstay treatment strategy 3 Her2neu negative prognostic parameter established strong foot holds breast cancer The ToGA trial Trastuzumab Gastric Cancer attributed similar status Her2neu gastric cancer unanimous consensus evolved far regards till 45 Prognostic factors defined staging therapeutic interventions gastric cancer imprecise patients similar para meters actually prove different levels clini cally attributing controversial prognostic status Her2neu overexpressivity 6 Ki67 p53 established prognostic markers tumors Ki67 useful predictive prog nostic marker cancers proliferation index exceeding 1014 delineating highrisk prognos tic category 7 A prechemotherapy evaluation rate Ki67 strong predictor efficacy therapy 8 p53 commonly mutated gene human cancer critical role cell cycle regulation tumor suppression In gastric lesions increasing frequency p53 mutations seen Hpylori infection key player gastric carcinogen esis intestinal metaplasia gastric dysplasia gastric carcinoma 9 Its expression associated advanced staged gastric carcinomas poorer postoperative prognosis In study p53 Ki67 assessed Her2neu positive negative gastric adenocarci noma GA idea association Her2neu status prognostic mar kers segregate subset aggres sive GA aggressive therapeutic approach requiring separate tailored aahmediauedusa CONTACT Ayesha Ahmed No articledata presented conference 2018 The Authors Published Informa UK Limited trading Taylor Francis Group This Open Access article distributed terms Creative Commons AttributionNonCommercial License httpcreativecommonsorglicensesbync40 permits unrestricted noncommercial use distribution reproduction medium provided original work properly cited 2 A AHMED AND D M ALTAMIMI 2 Material methods This cross sectional study carried Pathology Department King Fahd Hospital Imam Abdulrahman bin Faisal University 20152016 Approval protocol granted Institutional Review Board A sample size 45 sample implies biopsy specimen individual patient calcu lated study population registered patients 10000 confidence level 95 margin error 5 response rate 3 based cancer incidence report gastric cancer Saudi Arabia 2010 10 This sample drawn pathology archives department comprised gastric carcinoma resection specimens endoscopic biop sies period 10 years preceding study The inclusion criteria availability complete patient record representative paraffin blocks suf ficient tissue material perform required histo patholgical procedures A total 55 cases selected initially assumption cases qualify selection criteria time tissue processing staining However suc ceeded 50 qualifying samples reported 50 instead 45 GA histologically classified according Laurens 11 divides GA types intestinal consist ing wellformed tubules diffuse diffuse tumor infiltration wellformed tubules frequently signet ring cells Immunohistochemical staining labeled streptavidinbiotin method 33ʹdiaminobenzidine chromagen performed Her2neu p53 Ki67 4 µm paraffin sections cut conven tional blocks Prediluted antibodies Her2 neuclone CB11 Ki67clone MIB1 p53clone DO7 obtained Ventanna Dako Navacastro respectively The staining performed concurrently Ventana Benchmark automated immu nostainer according manufacturers instructions Ventana Medical Systems Inc Strasbourg France The immunostained sections examined light microscope evaluated manually interpretational discrepancies authors Any resolved doubleheaded microscope A modified scoring GA shown predictive large Phase III ToGA trial Her2neu expression gastric cancer 12 The 10 cutoff rule kept resection specimen biopsies group tumor cells showing distinct membranous staining typically lateral junctions considered specific The cellcell Microscope Magnification rule applied determine Her2neu expression Demonstration distinct intercellular membranous staining linear basolateral ringshaped required If strong intensity seen 255 magnification designated score 3 A visible weak moderate staining 1020 scored 2 barely visible staining 2040 scored 1 negative staining given score 0 A score 2 3 considered Her2neu positive expression While scores 0 1 regarded Her2neu negative 12 The unequivocal cases Her2 neu 2 confirmed FISH analysis FISH HER2 gene amplification conducted FFPE gastric tumor according protocol FDA approved kit Abbott The probes consist dual color probe mixture DNA sequences specific regions chromosome 17 including centromere chromosome 17 CEP17 Her2 gene region chromosome 17q12 Signals visualized Zeiss Axioskop microscope Zeiss Germany FITCRhodamine dual band filter We followed ASCO criteria analyzing results The guidelines stated Her2CEP17 ratio 2 considered normal result 2 considered amplified abnormal result Ki67 p53 Her2neu positive negative cases Frequency Ki67 p53 compared Her2neu positive negative cases statistical significance determined Ki67 expression defined presence nuclear staining The percentage cells expressing Ki67 determined counting 1000 cellsslide The percentage positive cells scored follows 10 low proliferative activity 1040 moder ate proliferative activity 40 high pro liferative activity 13 p53 mutation status defined positive presence nuclear staining Cytoplasmic staining considered negative Tumors considered focally positive unequivocal staining pre sent 1050 tumor cells diffusely posi tive 50 tumor cells positive 9 Data entered SPSS version 19 Descriptive statistics calculate frequencies percen tages expression Her2neu Ki67 proliferation index p53 mutation status Frequency Ki67 p53 positivity compared Her2neu posi tive negative cases Chi square test A P value 005 considered statistically significant 3 Results Out total 50 cases gastric cancer retrieved 43 specimens biopsies 7 partial gastrec tomies Male female ratio 3713 median age patients 67 years maximum minimum 88 42 years Diffuse type gastric cancer seen 23 46 intestinal type 27 54 cases The presented clinicopathological parameters Table 1 Cliniopathological parameters Her2neu positive negative gastric adenocarcinoma n 50 LIBYAN JOURNAL OF MEDICINE 3 Age years Gender Her 2 neu status 39 4050 50 M F Positive age n 6 Negative age n 44 6 100 0 29 15 34 66 6 100 16 36 0 28 64 0 0 Tumor site Tumor type Tumor grade Proximal Distal Diffuse Intestinal Low Well Mod High Poor 5 83 20 45 1 17 24 55 0 23 52 6 100 21 48 5Mod 83 15 34 1 17 29 66 Lymphovascular invasion ve 4 67 18 41 ve 2 33 26 59 Neural invasion ve ve 3 3 50 50 28 16 64 36 Table 1 The relationship Ki67 proliferation index p53 mutation status clinicopathological para meters presented Tables 2 3 Her2neu expression pattern given Table 4 Ki67 proliferation index p53 mutation In Her2neu status given Table 5 respectively positive negative cases p53 mutation status Ki67 proliferation index represented Tables 6 7 respectively Her2neu positivity cases Table 4 Diffuse p53 positivity seen 3333 n 2 Her2neu positive cases compared 1591 n 7 Her2neu negative cases Diffuse p53 signifi cantly high P value 001 Her2neu positive cases Table 6 Focal p53 positivity seen 3333 n 2 Her2neu positive cases compared 568 n 25 Her2neu negative cases Focal p53 significantly high P value 001 Her2neu negative cases Table 6 Negative p53 observed independent Her2neu status A high Ki67 seen 83 n 5 Her2neu positive cases compared 34 n 15 Her2neu Table 2 Relationship Ki67 proliferation index gastric adenocarcinoma n 50 clinicopathological parameters Tumor grade Lymphovascular invasion Neural invasion Ki67 proliferation index Mod high n 35 age 100 Low n 15 age 100 Low Well Mod 5 14 15 100 High Poor 30 86 0 0 ve 21 60 1 7 ve 14 40 14 93 ve ve 18 17 51 49 13 2 86 14 Table 3 Relationship p53 mutation status gas tric adenocarcinoma n 50 clinico pathological parameters Tumor grade Lymphovascular invasion Neural invasion p53 mutation status Focal n 27 age 100 Diffuse n 9 age 100 Negative n 14 age 100 Low Well Mod 15 56 2 22 3 21 High Poor 12 44 7 78 11 79 ve 9 33 8 89 5 36 ve 18 67 1 11 9 64 ve ve 19 8 70 30 2 7 22 78 10 4 71 29 Table 4 Her2neu expression gastric adenocarcinoma n 50 Her2 neu status Negative N Her2 neu staining intensity 0 1 2 3 age 86 2 8 4 43 1 4 2 Positive Her2neu 1 negative2 moderately positive3 strongly positive P 0001 chi square test Table 5 Ki67 proliferation index p53 mutation status gastric adenocarcinoma n 50 N age High 20 40 Ki67 Mod 15 30 Low 15 30 Focal 27 54 p53 Diffuse 9 18 Negative 14 28 negative cases High Ki67 significantly high P value 001 Her2neu positive cases Table 7 A moderate Ki67 seen 1666 n 1 Her2neu positive cases compared 3188 n 14 Her2neu negative cases Moderate Ki67 sig nificantly high P value 001 Her2 neu negative cases Table 7 A low Ki67 seen 0 n 0 Her2neu positive cases compared 34 n 15 Her2neu negative cases Low Ki67 significantly high P value 001 Her2 neu negative cases Table 7 4 Discussion Gastric cancer disease entity complex combination multiple genetic epigenetic alterations Marked variation prognosis patients GA similar pathological stage requires identification subgroups patients aggressive disease In study overall estimation Her2neu overexpression p53 mutation status Ki67 pro liferation index GA evaluation p53 Ki67 Her2neu positive Her2neu negative GA evaluated Overall study cumulative 12 Her2neu expressivity 8 showing 2 4 demonstrating 3 immunoreactivity Figure 1ab Her2neu expression GA reported range 117 14 23 15 different studies Only studies documented Her2neu protein overexpression gene amplification associated 4 A AHMED AND D M ALTAMIMI Table 6 Crosstab showing distribution p53 mutation status according Her2neu status gastric adenocarcinoma cases n 50 Her2neu expression Positive n 6 Negative n 44 Total n 6 2 n 4 3 n 2 Total n 44 1 n 1 0 n 43 Diffuse 2 3333 1 1 7 1591 0 7 Pvalue 001 chi square test p53 Focal 2 3333 1 1 25 5681 1 24 Negative 2 3333 2 0 12 2727 0 12 Table 7 Crosstab showing distribution Ki67 expression according Her2neu status gastric adenocarcinoma cases n 50 Her2neu expression Positive n 6 Negative n 44 Total n 6 2 n 4 3 n 2 Total n 44 1 n 1 0 n 43 High 5 83 3 2 15 34 1 14 Pvalue 001 chi square test Ki67 Mod 1 1666 1 0 14 3181 0 14 Low 0 0 0 0 15 34 0 15 b c d Figure 1 Her 2 neu 3 immunoreactivity associated high Ki67 proliferation index diffuse p53 mutation status Her2 neu3 20 b Her2 neu3 40 c High Ki67 20 d High Ki67 40 e Diffuse p53 20 f Diffuse p53 40 e f worse prognosis 16 larger studies confirm independent prognostic 1718 Her2neu prognostic significance factor minimized reported loss approximately patients treated trastuzumab leading drug resistance Additionally advanced aggressive Her2neu positive tumors genetic alterations involving specifically p53 92 cellcycle mediators supervene 19 These data sug gest need periodic Her2neu status evaluation therapy incorporation monitoring cell cycle regulators p53 start baseline level available patient evaluation In gastric carcinomas p53 expression frequency reported vary 46 20 61 21In set cases total 72 cases revealing focal diffuse p53 expression Figure 1ef somewhat higher representation seen Out Her2neu posi tive cases predominantly showed diffuse p53 positivity 3333 Her2neu negative cases 5681 revealed focal p53 positivity Negative p53 expression seen irrespective Her2neu status This stratification p53 Her2neu expression pat tern reported p53 mutation common genetic alterations human cancer initiation progression reported independent prognostic factor patients overall diseasefree survival gastric cancer 22 A strati fied expression seen cases increase focal Her2neu negative diffuse Her2neu posi tive cases Could point direct genetic link entities increasing concomitantly codependent inde pendent factors Therapeutically link important cur rently antip53 therapies 23 stages devel opment Addition antiHer2neu drugs traztuzumab improve patients clinical outcome poor till Based discussion Her2neu p53 cases categorized groups One set Her2neu positive cases retain p53 expression lose Her2neu expression cancer advanced This set ones facing traztuzumab resistance Addition antip53 helpful extent The set ones conjoined expression Her2neu diffuse p53 A double therapy target ing beneficial patients More extensive studies unravelling facts genetic clinical levels need carried In study overall high moderate Ki67 prolif erating index seen 70 cases A range 70 76 reported studies 2425 Ki67 nuclear protein expressed proliferating cells cell cycle In metaanalysis comprising LIBYAN JOURNAL OF MEDICINE 5 total 5600 gastric cancer patients 29 studies concluded high Ki67 expression serve predictive biomarker poor prognosis gastric cancer patients 26 The value Ki67 marked seen conjunction Her2neu positiv ity An association Her2neu overexpression Ki 67 proliferation index high grade stage reported 27 In study 83 Her2neu positive cases showed high Ki67 proliferation index Figure 1b c Her2 neu negative cases revealed mainly moderate low Ki67 Hence Ki67 expression increases Her2 neu overexpression Could concept Her2 neu gene working independent prognostic marker needs reevaluated At genetic level Her2neu Ki67 maybe partners express collectively high grade advanced gastric carcinomas The protein expres sion Ki67 Her2neu overlapping features clinical pathologic characteristics gastric cancer Ki 67 strongly linked gastric cancer differentiation infiltration lymphatic spread Her2 neu plays role level tumor differentiation nodal metastasis 28 Stratification cases Her2neu status extent Ki67 expression useful tool selection specific therapies Ki67 molecular target anticarcinogenic therapies explored 29 A advanced gastric cancer genetic profiling needs determined formulation molecular classification gastric cancer currently breast cancer This pave way individualized targeted treatment options based gastric cancer molecular characteristics improve patients prognostics dismal till 5 Conclusion Her2neu positivity strongly associated diffuse p53 mutation status high Ki67 proliferation Her 2neu negative status associated focal p53 positivity low moderate Ki67 proliferation index This strong association Her2neu positive cases basis separate molecular subset gastric carcinoma potential candidate separate tailored molecular therapeutic regimens Disclosure statement No potential conflict authors reported Funding This work supported Imam Abdulrahman Bin Faisal University Formerly University Dammam Grant No 2011011 6 A AHMED AND D M ALTAMIMI ORCID Ayesha Ahmed httporcidorg0000000220367067 References 1 Son HS Shin YM Park KK et al Correlation HER2 overexpression clinicopathological character istics gastric cancer patients undergone curative resection J Gastric Cancer 2014 Sep14 3180186 2 Ferlay J Soerjomataram I Dikshit R et al Cancer inci dence mortality worldwide sources methods major patterns GLOBOCAN 2012 Int J Cancer 2015 Mar 11365E359E386 3 Ieni A Barresi V Rigoli L et al HER2 status prema lignant early advanced neoplastic lesions stomach Dis Markers 20152015234851 doi 101155 2015234851 4 Bang Y Chung H Xu J et al Pathological features advanced gastric cancer GC relationship human epidermal growth factor receptor 2 HER2 positivity global screening programme ToGA trial J Clin Oncol 2009 May 202715S4556 5 Iqbal N Iqbal N Human epidermal growth factor receptor 2 HER2 cancers overexpression ther apeutic implications Mol Biol Int 20142014852748 6 Wang HB Liao XF Zhang J Clinicopathological factors associated HER2positive gastric cancer meta analysis Medicine 2017 Nov 19644e8437 7 Amrani HJ Marchoudi N Sadaoui I et al Ki67 expres sion gastric cancer correlation clinico pathological characteristics Int J Sci Res Publ 20144 6254258 8 Shien T Kinoshita T Seki K et al p53 expression pretreatment specimen predicts response neoadju vant chemotherapy including anthracycline taxane patients primary breast cancer Acta Med Okayama 2013673165170 9 Busuttil RA Zapparoli GV Haupt S et al Role p53 progression gastric cancer Oncotarget 2014 Dec52312016 10 Cancer incidence report Saudi Arabia Kingdom Saudi Arabia Council health services Saudi cancer registry April 2014 cited 2015 Jun 4 Available wwwscrorgsa 11 Hu B El Hajj N Sittler S et al Gastric cancer classifica tion histology application molecular pathology J Gastrointest Oncol 2012 Sep33251261 12 Van Cutsem E Kang Y Chung H et al Efficacy results ToGA trial phase III study trastuzumab added standard chemotherapy firstline HER2posi tive advanced gastric cancer J Clin Oncol 20092715s 13 Saricanbaz I Karahacioglu E Ekinci O et al Prognostic significance expression CD133 Ki67 gastric cancer Asian Pac J Cancer Prev 2014151982158219 14 Kataoka Y Okabe H Yoshizawa A et al HER2 expres sion clinicopathological features resectable gastric cancer Gastric Cancer 2013 Jan 11618493 15 Phillips BE Tubbs RR Rice TW et al Clinicopathologic features treatment outcomes patients human epidermal growth factor receptor 2positive ade nocarcinoma esophagus gastroesophageal junction Dis Esophagus 2013 Apr 1263299304 16 Tanner M Hollmen M Junttila TT et al Amplification HER2 gastric carcinoma association topoi somerase IIα gene amplification intestinal type poor prognosis sensitivity trastuzumab Ann Oncol 2005 Feb 1162273278 17 Aizawa M Nagatsuma AK Kitada K et al Evaluation HER2based biology 1006 cases gastric cancer Japanese population Gastric Cancer 2014 Jan 117 13442 18 Terashima M Kitada K Ochiai A et al Impact expres sion human epidermal growth factor receptors EGFR ERBB2 survival stage IIIII gastric cancer Clin Cancer Res 2012 Sep 121859926000 clincanres 1318 19 Janjigian YY Riches JC Ku GY et al Conference Gastrointestinal Cancers Symposium Journal Clinical Oncology 2015333 Supplement Meeting Abstract 63 20 Choi WH Lee S Cho S Microsatellite alterations protein expression 5 major tumor suppressor genes gastric adenocarcinomas Transl Oncol 2018 Feb 281114355 21 Babacan NA Eğilmez HR Yücel B et al The prognostic value UHRF1 p53 gastric cancer Saudi J Gastroenterol 2016 Jan22125 22 Yıldırım M Kaya V Demirpence O et al Prognostic significance p53 gastric cancer metaanalysis Asian Pac J Cancer Prev 2015161327332 23 Duffy MJ Synnott NC McGowan PM et al p53 target treatment cancer Cancer Treat Rev 2014 Dec 31401011531160 24 Zheng Y Wang L Zhang JP et al Expression p53 cerbB2 Ki67 intestinal metaplasia gastric carcinoma World J Gastroenterol 2010 Jan 2116 3339 25 Lazăr DA Tăban SO Sporea I et al Ki67 expression gastric cancer Results prospective study longterm followup Rom J Morphol Embryol 201051 4655661 26 Luo G Hu Y Zhang Z et al Clinicopathologic signifi cance prognostic value Ki67 expression patients metaanalysis Oncotarget 2017 Jul 2583050273 cancer gastric 27 Ieni A Barresi V Giuffrè G et al HER2 status advanced gastric carcinoma retrospective multi centric analysis Sicily Oncol Lett 2013 Dec 16 615911594 28 ElGendi S Talaat I AbdelHadi M HER2Neu status gastric carcinomas series Egyptian patients relation Ki67 expression Open J Pathol 2015 Aug 1754101 29 Wang S HüTtmann G Zhang Z et al Lightcontrolled delivery monoclonal antibodies targeted photo inactivation Ki67 Mol Pharm 2015 Aug 1312 932723281